A preliminary investigation of laterality in Parkinson's disease and susceptibility to psychosis

Shergill, Sukhwinder S.; Walker, Zuzana; Katona, Cle

doi:10.1136/jnnp.65.4.610

Cited by 19 publications

(16 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prevalence studies consistently found hallucinations [9,21,40,44,45] (Table 2) as well as delusions [44] to be significantly more frequent in demented than non-demented PD patients. In line with this, both cross-sectional and longitudinal studies identified cognitive impairment and dementia to be independent risk factors for hallucinations [9,21,31,40,43,44,46]. In patients with early PD, a lower MMSE at baseline was associated with a higher risk of developing hallucinations on treatment [29].…”

Section: Cognitive Impairmentmentioning

confidence: 62%

Epidemiology of psychosis in Parkinson's disease

Fénelon

Alves

2010

Journal of the Neurological Sciences

283

213

View full text Add to dashboard Cite

Section: Cognitive Impairmentmentioning

confidence: 62%

Epidemiology of psychosis in Parkinson's disease

Fénelon

Alves

2010

Journal of the Neurological Sciences

283

213

View full text Add to dashboard Cite

“…In two prospective [14,33] and one retrospective study [35], hallucinations were not associated with the dosage of dopaminergic medication (levodopa or dopaminergic agonists). Furthermore, when high dose levodopa infusions were administered in five non-demented patients with PD and hallucinations in a placebo controlled trial, no hallucinations were provoked [10].…”

Section: Discussionmentioning

confidence: 96%

Factors associated with drug–induced visual hallucinations in Parkinson's disease

2005

View full text Add to dashboard Cite

show abstract

“…Previous studies have found that there is no dose-effect relationship between the use of dopaminergic agents and development of hallucinations [24]. In fact, two prospective studies and one retrospective study showed no association between use of L-dopa or DAs and development of hallucinations [15] [26] [27]. In addition, a study by Goetz et al in 1998 showed that there was no simple relationship between the development of visual hallucinations and high plasma levels of L-dopa or sudden changes in plasma levels [28].…”

Section: Discussionmentioning

confidence: 94%

“…In addition, it is estimated that one-quarter to one-third of PD patients will experience hallucinations [13]. Hallucinations have been associated with L-dopa therapy, older age, and longer duration of the disease [14] [15]. However, they are now perceived to be a result of complex interactions between PD medications and PD pathophysiology [16].…”

Section: Introductionmentioning

confidence: 99%

Medication Side Effect Profiles in PD Patients in a Safety-Net Hospital

Sisniega¹,

Madhusudhan²,

Rahmani³

et al. 2017

APD

View full text Add to dashboard Cite

Background: Compulsive behavior, dyskinesias, motor fluctuations, and hallucinations are common Parkinson's disease (PD) medication side effects.These are yet to be examined in relation to race and level of education. The goal of this analysis was to identify socioeconomic or clinical variables that are associated with compulsive behavior, dyskinesias, motor fluctuations, and hallucinations in patients in a safety-net hospital. Methods: A movement disorder patient database containing 452 patients with idiopathic PD was analyzed for differences in PD medication side effects using univariate and multivariate logistic regression analysis. Race, sex, and level of education were evaluated as possible confounders. Results: A greater proportion of the patients in this study were Caucasian males. The only variable associated with compulsive behavior was age, with higher age having a protective effect (p = 0.0336). Disease duration (defined as time since the onset of symptoms), diagnosis duration (time since formal diagnosis), and level of education were significantly associated with dyskinesia inunivariate analysis (p =< 0.0001, <0.0001, 0.1236 respectively). However, diagnosis duration was the only variable significantly associated with dyskinesia in multivariate analysis (p = 0.0038), in addition to a borderline significant association when comparing individuals with graduate degree to those who had completed high school education or less (p = 0.0599), with a protective effect of higher education. Disease duration, diagnosis duration, and use of monoamineoxidase inhibitors were also significantly associated with motor fluctuations in the univariate analysis, while only diagnosis duration was significantly associated with motor fluctuations in multivariate analysis (p = 0.0035) with longer diagnosis duration associated with higher risk of motor fluctuations. Age, disease duration, and diagnosis duration were associated with an increased risk of hallucinations

show abstract

A preliminary investigation of laterality in Parkinson's disease and susceptibility to psychosis

Cited by 19 publications

References 3 publications

Epidemiology of psychosis in Parkinson's disease

Epidemiology of psychosis in Parkinson's disease

Factors associated with drug–induced visual hallucinations in Parkinson's disease

Medication Side Effect Profiles in PD Patients in a Safety-Net Hospital

Contact Info

Product

Resources

About